MedTrace Logo

Prevention of Recurrent Venous Thromboembolism (PREVENT)

NCT00000614 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-03-16

No results posted yet for this study

Summary

A multicenter randomized, double blind placebo controlled trial to determine the efficacy of long-term, low dose warfarin in the secondary prevention of venous thromboembolism.

Conditions

  • Cardiovascular Diseases
  • Heart Diseases
  • Peripheral Vascular Diseases
  • Thromboembolism
  • Vascular Diseases
  • Venous Thromboembolism

Interventions

DRUG

warfarin

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Robert Glynn · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-09-30
Completion
2004-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000614 on ClinicalTrials.gov